What is the POSSIBLE Diagnostic Program?
POSSIBLE, which stands for PrecisiOn teSting for metaStatIc and resectaBLE lung cancer, is a collaboration
between AstraZeneca and Oncode. It aims to enhance the accessibility and affordability of NGS testing for lung
cancer patients, turning precision medicine into a reality. The eligibility criteria of POSSIBLE encompass individuals
newly diagnosed with NSCLC, regardless of stage, as well as those with recurrent or progressive disease from
previous therapy.
POSSIBLE, which stands for PrecisiOn teSting for metaStatIc and resectaBLE lung cancer, is a collaboration between AstraZeneca and Oncode. It aims to enhance the accessibility and affordability of NGS testing for lung cancer patients, turning precision medicine into a reality. The eligibility criteria of POSSIBLE encompass individuals newly diagnosed with NSCLC, regardless of stage, as well as those with recurrent or progressive disease from previous therapy.
Test Description
POSSIBLE is a 17-gene NGS panel designed for lung cancer, targeting mutations and fusions in genes which have
clinical relevance and actionability in the treatment of lung cancer.
POSSIBLE is a 17-gene NGS panel designed for lung cancer, targeting mutations and fusions in genes which have clinical relevance and actionability in the treatment of lung cancer.
Eligibility Criteria
Newly diagnosed NSCLC, any stage, or
Patient recurred from Early-stage NSCLC, or
Patient progress on previous therapy in advanced/metastatic stage.
Histology: Adenocarcinoma, Squamous cell carcinoma, and Large cell carcinoma.
If you have any questions or would like to learn more about the POSSIBLE Program, please do not hesitate to contact us
MY-13505_FEB2024